Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
FDA OKs Study of Amezalpat in Frontline Liver Cancer
Nov 13, 2024 · The clinical and regulatory team at Tempest are thrilled to receive this notice from FDA with respect to the planned pivotal phase 3 trial to evaluate amezalpat as a potential treatment for first-line liver cancer,” said Sam Whiting MD, PhD, chief medical officer and head of research and development of Tempest, in a press release. 1 “Previously reported positive phase 2 data underscore ...
FDA Approves IND for AS1986NS, a New Approach in Prostate …
Nov 15, 2024 · The investigational new drug (IND) application for AS1986NS, a novel prostate cancer diagnostic and treatment agent, has received FDA approval.
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.
Key Advances in Oncology: Top Highlights From ESMO 2024
Sep 18, 2024 · This year's 2024 ESMO Congress brought forth a wave of groundbreaking developments poised to shape the future of oncology. As an essential platform for sharing pivotal cancer research and innovative clinical practices, the ESMO Congress continues to foster vital discourse among the medical community.
FDA Approves Zanidatamab in HER2+ Biliary Tract Cancer
Nov 21, 2024 · The FDA granted an accelerated approval to zanidatamab-hrii (Ziihera) for the treatment of patients with previously treated, unresectable or metastatic HER2-positive (HER2+) biliary tract cancer. This is the first HER2-targeted treatment specifically approved in …
September 2024 FDA Roundup: Key Decisions Drive Oncology …
Oct 2, 2024 · FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML. ICT01, a humanized anti-BTN3A monoclonal antibody, plus azacitidine and venetoclax (Venclexta) earned fast track designation for the treatment of acute myeloid leukemia in patients 75 or older or those who have comorbidities that preclude standard induction chemotherapy on …
Multidisciplinary Approach to Thyroid Cancer Management
Nov 19, 2024 · Noah S. Kalman, MD, MBA, a radiation oncologist specializing in the treatment of gynecologic, head and neck, thoracic, and pediatric cancers at Miami Cancer Institute of Baptist Health Medical Group, discusses how oncologists can determine the best course of action for the treatment and management of a patient with thyroid cancer.
Positive Trials Continue to Shape the SCLC Treatment Landscape
Nov 8, 2024 · Recent advancements in small cell lung cancer (SCLC) treatments have introduced transformative therapies and trial results, according to Ariel Lopez-Chavez MD.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...